You just read:

EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

News provided by

EUSA Pharma

Mar 27, 2017, 04:00 ET